Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 20/20 | 0.55 |
| ▸ | PFKFB1 | P16118 | 19/20 | 0.55 |
| ▸ | PFKFB2 | O60825 | 16/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10095949 | 0.87 | KDM4E (0.45) | — | |
| SCHEMBL10095321 | 0.87 | MTNR1A (0.47) | PFKFB3PFKFB1PFKFB2 | |
| SCHEMBL10095374 | 0.86 | PFKFB3 (0.53) | PFKFB3PFKFB1PFKFB2 | |
| SCHEMBL12923068 | 0.83 | GRIK2 (0.46) | PFKFB3PFKFB1PFKFB2 | |
| SCHEMBL982759 | 0.82 | GRIK2 (0.46) | PFKFB3PFKFB1PFKFB2 | |
| SCHEMBL10097246 | 0.81 | PFKFB2 (0.47) | PFKFB3PFKFB1PFKFB2 | |
| SCHEMBL10096372 | 0.81 | SMN1; SMN2 (0.51) | PFKFB3PFKFB1PFKFB2 | |
| SCHEMBL10095947 | 0.81 | MTNR1B (0.49) | PFKFB3PFKFB1PFKFB2 | |
| SCHEMBL10096389 | 0.80 | SMN1; SMN2 (0.53) | — | |
| SCHEMBL10095989 | 0.80 | GRIK2 (0.47) | PFKFB3PFKFB1PFKFB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | PFKFB3 4231/4885PFKFB1 4102/4885PFKFB2 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.